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Abstract
Anaphylaxis is defined as a severe life-threatening generalized or systemic hypersensitivity reaction. The difficulty of
coding anaphylaxis fatalities under the World Health Organization (WHO) International Classification of Diseases
(ICD) system is recognized as an important reason for under-notification of anaphylaxis deaths. On current death
certificates, a limited number of ICD codes are valid as underlying causes of death, and death certificates do not
include the word anaphylaxis per se. In this review, we provide evidences supporting the need for changes in WHO
mortality coding rules and call for addition of anaphylaxis as an underlying cause of death on international death
certificates. This publication will be included in support of a formal request to the WHO as a formal request for this
move taking the 11th ICD revision.
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Background
Anaphylaxis definition and epidemiology
Definitions of anaphylaxis for clinical use by healthcare
professionals all state the concepts of a serious, general-
ized, allergic or hypersensitivity reaction that can be life-
threatening and even fatal [1]. In all countries, epidemio-
logical and health services research can serve as a baseline
for quality improvement, prioritization of anaphylaxis pro-
grams, and eventual reduction in morbidity and mortality.
Publications on anaphylaxis epidemiological data have
increased in the past few years due to the need to under-
stand the status and evolution of this disease more pre-
cisely worldwide, improve in order to plan national or
global actions to support better management and pre-
vention globally and nationally, and support education
and awareness. Data can differ widely depending on a
number of variables. For instance, European data have
indicated incidence rates for all-cause anaphylaxis
ranging from 1.5 to 7.9 per 100 000 person/year, with an
estimation that 0.3% (95% CI 0.1–0.5) of the population
will experience anaphylaxis at some point during their
lifetime [2]. On the other hand, it is estimated that 1 in
every 3000 inpatients in US hospitals suffer from an
anaphylactic reaction with a risk of death around 1%,
accounting for 500 to 1000 deaths annually in this
country [3].
In public health terms, anaphylaxis is considered to be
an uncommon cause of death [4–9]. The case fatality
rate is difficult to ascertain with accuracy. Accurate
anaphylaxis mortality data are hampered by the limited
recognition of this condition among health professionals,
the absence of historical details from eyewitnesses,
incomplete death scene investigations, paucity of specific
pathologic findings at postmortem examination, and the
under-notification of anaphylaxis [9, 10].
Vital statistics: historical background and current
standard methods
The first International List of Causes of Death was
drafted by Jacques Bertillon and colleagues in 1885. It
was prepared based on the principle of distinguishing
between systemic diseases and those localized to a par-
ticular organ or anatomical site, and officially adopted
for use in mortality registries in 1893 [11]. This
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classification, which was accepted by many countries
and has been periodically revised, constituted the basis
of the International Classification of Diseases (ICD).
Anaphylaxis was not included in the original list because
it was not formally described until 1902 [12]. Although a
well-known cause of death, particularly in the fields of
allergy and emergency medicine, anaphylaxis has never
been appropriately classified in the different versions of
the ICD, and has never been considered an underlying
cause of death on death certificates.
Mortality statistics are widely used for medical re-
search, monitoring of public health, evaluating health in-
terventions and planning and follow-up of health care.
Analysis of mortality data typically involves comparisons
of data sets. However, unless the data have been com-
piled using the same methods and according to the same
standards, comparisons potentially yield misleading re-
sults. For these reasons, the World Health Organization
(WHO) issued international instructions on data collec-
tion, coding and classification, and statistical presenta-
tion of causes of death. In most countries, mortality
statistics are routinely compiled according to regulations
and recommendations adopted by the World Health
Assembly (WHA). The international mortality coding
instructions presuppose that data have been collected
with a death certificate conforming to the International
form of medical certificate of cause of death (Fig. 1) [13].
It is the responsibility of the medical practitioner or other
qualified certifier signing the death certificate to indicate
which morbid conditions led directly to death and to state
any antecedent conditions giving rise to this cause.
The international death certificate form is split in 2 parts
(Fig. 1). Part 1 is for diseases or conditions related to the
sequence of events leading directly to death, and Part 2 is
for unrelated but contributory conditions. The terminal
cause of death is the condition entered first on the first line
of Part 1 of the death certificate. The underlying cause of
death is the condition selected for such single-cause tabu-
lation. In most cases, the underlying cause of death is the
same as the starting point of the sequence described in
Part 1. Special coding instructions on specific sequences
and ICD categories may have the effect that a condition
other than the starting point is selected as the underlying
cause of death for use in the vital statistics [13].
If an apparent error is found in the mortality data no-
tification, it should be reported to the WHO, which will
either explain the rationale or take steps to correct the
error at the international level. Individual countries
should not correct what is assumed to be an error, since
changes at the national level will lead to data that are
not comparable to data from other countries, and thus
less useful for analysis [13].
Anaphylaxis mortality data: unmet needs
Allergic and hypersensitivity conditions in the ICD-11
Anaphylaxis mortality epidemiological data are sparse. Be-
sides the different methods used and the different popula-
tions studied (Table 1), the lack of standardized definitions
for this condition in the WHO ICD [1, 10, 14] is a recog-
nized challenge for the development of accurate and com-
parable population-based vital statistics in the field.
Causes of deaths are classified and grouped according
to the ICD edition in use at the time, currently ICD-10
(and adaptations), and the information on vital statistics
is collected using the international form recommended
by the WHO. However, on the current death certificates,
a limited number of ICD-10 codes are considered to be
valid for representing underlying causes of death. As an
example, research showed an under-notification of ana-
phylaxis deaths due to difficult coding under the ICD-10
Fig. 1 The World Health Organization’s International form of medical certificate of cause of death
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using the Brazilian national mortality database, given that
there are no anaphylaxis-specific ICD-10 codes which are
considered valid for coding underlying causes-of-death [10].
Taking the window of opportunity presented by the on-
going ICD-11 revision, the under-notification of death
data [10] triggered a cascade of strategic international ac-
tions supported by the Joint Allergy Academies and the
ICD WHO governance [15–25] to update the classifica-
tions of allergic conditions for the new ICD edition. These
efforts have resulted in the construction of the new
“Allergic and hypersensitivity conditions” section under
the “Disorders of the Immune system” chapter [21, 26].
Here, in order to deliberate the new frame and follow
the ICD-11 revision agenda, we reviewed the forms on
which anaphylaxis has been classified in the ICD and the
published anaphylaxis fatalities data, particularly with
regards to the methods used for death notification. We
also propose modifications in the WHO mortality cod-
ing rules under the 11th revision of the ICD context.
Status of anaphylaxis in the ICD-10 and the ICD-11 Beta
draft
The search for the term “anaphylaxis” in the online ver-
sions of the ICD-10 (2016 version) [27] and of the ICD-
11 Beta draft Linearization (July 2016 version) [26]
allows us to demonstrate the main differences resulted
from all the efforts over the last 4 years (Fig. 2). The
ICD-10 inherited the hierarchical scheme of the previous
ICD versions, essentially based in main organs or main
cause (infectious diseases or external causes). Therefore,
some systemic conditions such as anaphylaxis were ad-
justed in the chapter related to external causes. As a re-
sult of our search into the ICD-10 (2016 version)
platform, we have addressed the “XIX Injury, poisoning
and certain other consequences of external causes”
chapter, specifically the “T78 Adverse effects, not else-
where classified” section. In Fig. 2 (highlighted in red)
we also underline the lack of awareness of allergic and
hypersensitivity concepts verified in the T78 section.
Under this section it is possible to observe that only se-
vere cases of anaphylaxis have been prioritized (T78.2
Anaphylactic shock), which was classified at the same
level of “Anaphylactic shock due to adverse food reac-
tion”, “Angioneurotic oedema” and “Allergy, unspeci-
fied”. In fact, obstruction of the upper and/or lower
respiratory tract leading to respiratory distress and po-
tential fatality is more commonly observed in anaphyl-
axis than hypotension and shock per se. It is also
possible to note the misclassification implied in the
ICD-10 exemplified by scattering “T78.2 Anaphylactic
shock” at the same level of the “T78.3 Angioneurotic
oedema”, “T78.4 Allergy, unspecified” and “T78.9 Ad-
verse effect, unspecified” under the same heading (Fig. 2,
in bold).
In the new “Allergic and hypersensitivity conditions”
section of ICD-11, it was possible to build a sub-section
specifically addressed to anaphylaxis. For the first time,
anaphylaxis is elected as individualized conditions into the
ICD-11 frame, receiving a sub-section addressed to this
condition. Currently, this subsection contains 7 main ana-
phylaxis headings to be post-coordinated with severity
and causality classification/specifications, still under tun-
ing. The building block of this framework was the result
of combined efforts and constant discussions with the
groups of experts and the ICD WHO governance.
Based on the ICD-10 codes, some external stimuli are
considered as underlying causes-of-death, but the word
anaphylaxis as such has never been listed as an un-
derlying cause-of-death. In fact, having allergic and
hypersensitivity conditions classified in a more detailed
scheme in the ICD-11 and not as in ICD-10 into a spe-
cific chapter in the “External causes of morbidity and
mortality” or in the “Injury, poisoning and certain other
consequences of external causes” chapters allows for
capture of more realistic anaphylaxis mortality data from
now on.
What do the published fatal anaphylaxis data tell us?
Constructing a classification of anaphylaxis for ICD-11
was a challenge; however, it was important to align this
with the published post-mortem anaphylaxis epidemio-
logical data. From 30th June 2015 to 4th December 2015,
thirty manuscripts were selected using PubMed Mesh
terms “anaphylaxis deaths”, “anaphylaxis mortality”,
“anaphylaxis fatalities”, covering documents published in
the last five decades. We did not include case reports as
such (with the exception of a few landmark case series),
studies in animal models or reviews. All publications
were independently evaluated by two co-authors and
disagreements related to the inclusion into the analysis
were resolved through open discussion. We analyzed
methodological aspects, main outcomes and databases
used in the remaining 22 publications (Table 1), 45% of
which focused on specific triggers or etiology. Most of
these documents (64%) were published over the last
15 years. The methods used and the population evalu-
ated varied among the publications; however, 54.5% fo-
cused on US populations in different centers. Overall,
54% were based on national databases and 36.4% of
these documents used the ICD for mortality registries as
the basis of the analysis (as highlighted in bold in
Table 1), with 62.5% being population-based studies.
Based on ICD registries, regardless of the ICD version
used, 87.5% of all the studies had to utilize secondary
data in death certificates in order to capture the ana-
phylaxis data. Studies of anaphylaxis mortality using sec-
ondary data require the use of information derived from
the underlying as well as the contributing cause-of-
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death. In other words, none of these deaths would have
been found had the authors exclusively considered infor-
mation from the underlying cause-of-death field.
Conclusion
Data support changes in the world health organization
anaphylaxis mortality coding rules
In summary, in this manuscript, we provide evidence that
supports the need for changes in the WHO mortality
coding rules by adding anaphylaxis as an underlying
cause of death in international death certificates. This art-
icle is a contribution to the establishment of ICD-11 to
ensure a proper coding of anaphylaxis, in order to gener-
ate an accurate knowledge of the consequences of this se-
vere condition. This document will comprise part of a
formal request to the WHO to change mortality coding
rules so that anaphylaxis can be listed as an underlying
cause of death in international death certificates.
The only reference for 
food allergy 
The ICD-10 elects just severe
cases of anaphylaxis 
Misclassification
Fig. 2 Anaphylaxis in International Classification of Diseases (ICD)-10 (2016 version) and ICD-11 Beta draft (July 2016 version). In bold, the headings
of the ICD-10 T78 section and, in red, comments regarding misclassification of allergic and hypersensitivity conditions
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Once implemented by the WHO, there will be two im-
mediate consequences of the use of the new classification
based on the logic of the ICD-11: (i) although currently
anaphylaxis fatalities are perceived as rare, the reported
number of anaphylaxis deaths may increase [28] and (ii)
most cases will be included in official mortality statistics,
providing a global standard for comparability and, there-
fore, for decision-making and prevention.
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